REGENERON PHARMACEUTICALS (REGN) Stock Price, Quote, News and Summary
NASDAQ:REGN - Nasdaq - US75886F1075 - Common Stock
REGN Quote and Key Statistics
REGENERON PHARMACEUTICALS
NASDAQ:REGN (1/17/2025, 8:24:08 PM)
After market: 681.58 0 (0%)681.58
-11.65 (-1.68%)
REGN Financial Highlights
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 33.61% | ||
| ROA | 12.43% | ||
| ROE | 15.87% | ||
| Debt/Equity | 0.09 |
REGN Performance and Technical Analysis
REGN Ownership and Analysts
REGN Latest News and Analysis
Tuesday's session: top gainers and losers in the S&P500 index
Top S&P500 movers in Tuesday's session
REGN INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Regeneron Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
/PRNewswire/ -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit...
REGN Investors Have Opportunity to Lead Regeneron Pharmaceuticals, Inc. Securities Fraud Lawsuit
/PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of securities of...
Regeneron Pharmaceuticals, Inc. Class Action: The Gross Law Firm Reminds Regeneron Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of March 10, 2025 - REGN
/PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN). Shareholders who purchased...
About REGN
Company Profile
Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. The company is headquartered in Tarrytown, New York and currently employs 13,450 full-time employees. The firm invents, develops, manufactures, and commercializes medicines for people with serious diseases. Its products and product candidates in development are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, neurological diseases, hematologic conditions, infectious diseases, and rare diseases. The firm helps in accelerating and improving the traditional drug development process through its VelociSuite technologies, such as VelocImmune, which uses genetically humanized mice to produce optimized fully human antibodies and bispecific antibodies, and through ambitious research initiatives such as the Regeneron Genetics Center. Its marketed products include EYLEA (aflibercept) Injection; Dupixent (dupilumab) Injection; Libtayo (cemiplimab) Injection; Praluent (alirocumab) Injection; Kevzara (sarilumab) Injection, and others.
Company Info
REGENERON PHARMACEUTICALS
777 Old Saw Mill River Road
Tarrytown NEW YORK 10591 US
CEO: Leonard S. Schleifer
Employees: 13926
Company Website: https://www.regeneron.com/
Investor Relations: https://investor.regeneron.com/
Phone: 17813705000
REGN Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 15.96 | 303.17B | ||
| AMGN | AMGEN INC | 14.16 | 146.27B | ||
| GILD | GILEAD SCIENCES INC | 20.73 | 114.46B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 827.45 | 108.68B | ||
| ARGX | ARGENX SE - ADR | N/A | 38.30B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 31.76B | ||
| BNTX | BIONTECH SE-ADR | N/A | 26.97B | ||
| ONC | BEIGENE LTD-ADR | N/A | 22.37B | ||
| NTRA | NATERA INC | N/A | 20.91B | ||
| BIIB | BIOGEN INC | 8.61 | 20.48B | ||
| UTHR | UNITED THERAPEUTICS CORP | 15.76 | 16.02B | ||
| NBIX | NEUROCRINE BIOSCIENCES INC | 38.41 | 14.51B |